Advanced search
1 file | 792.47 KB

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1)

Author
Organization
Abstract
Objective: To evaluate the effect of secukinumab on patient-reported outcomes (PROs) in subjects with active psoriatic arthritis (PsA) in the FUTURE 1 study. Methods: Subjects were randomised 1:1:1 to receive intravenous (i.v.) secukinumab 10 mg/kg at weeks 0, 2 and 4 followed by subcutaneous secukinumab 150 or 75 mg every 4 weeks or matching placebo until week 24. Results: At week 24, subjects receiving secukinumab i.v. -> 1 50 mg or i.v. -> 75 mg reported greater least squares mean changes from baseline than those receiving placebo in patient global assessment of disease activity (-20.6 and -20.0 vs -7.4, respectively), patient assessment of pain (-20.8 and -20.4 vs -6.7), psoriatic arthritis quality of life (-3.5 and -3.2 vs -0.4), Dermatology Life Quality Index (-8.8 and -7.9 vs 0.7); p<0.0001 vs placebo for both secukinumab groups for above PROs and Functional Assessment of Chronic Illness Therapy-Fatigue (6.74 (p<0.05 vs placebo) and 6.03 vs 4.00); all of which well exceeded minimum clinically important differences. Conclusions: In subjects with PsA, secukinumab treatment resulted in clinically meaningful improvements in global disease activity, pain, generic and disease-specific measures of health-related quality of life and fatigue.
Keywords
QUALITY-OF-LIFE, RHEUMATOID-ARTHRITIS, ANKYLOSING-SPONDYLITIS, PERSPECTIVE, CRITERIA, FATIGUE

Downloads

    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 792.47 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Strand, Vibeke, Philip Mease, Laure Gossec, Ori Elkayam, Filip Van den Bosch, James Zuazo, Luminita Pricop, and Shephard Mpofu. 2017. “Secukinumab Improves Patient-reported Outcomes in Subjects with Active Psoriatic Arthritis : Results from a Randomised Phase III Trial (FUTURE 1).” Annals of the Rheumatic Diseases 76 (1): 203–207.
APA
Strand, V., Mease, P., Gossec, L., Elkayam, O., Van den Bosch, F., Zuazo, J., Pricop, L., et al. (2017). Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1). ANNALS OF THE RHEUMATIC DISEASES, 76(1), 203–207.
Vancouver
1.
Strand V, Mease P, Gossec L, Elkayam O, Van den Bosch F, Zuazo J, et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1). ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):203–7.
MLA
Strand, Vibeke, Philip Mease, Laure Gossec, et al. “Secukinumab Improves Patient-reported Outcomes in Subjects with Active Psoriatic Arthritis : Results from a Randomised Phase III Trial (FUTURE 1).” ANNALS OF THE RHEUMATIC DISEASES 76.1 (2017): 203–207. Print.
@article{8502214,
  abstract     = {Objective: To evaluate the effect of secukinumab on patient-reported outcomes (PROs) in subjects with active psoriatic arthritis (PsA) in the FUTURE 1 study. 
Methods: Subjects were randomised 1:1:1 to receive intravenous (i.v.) secukinumab 10 mg/kg at weeks 0, 2 and 4 followed by subcutaneous secukinumab 150 or 75 mg every 4 weeks or matching placebo until week 24. 
Results: At week 24, subjects receiving secukinumab i.v. -{\textrangle} 1 50 mg or i.v. -{\textrangle} 75 mg reported greater least squares mean changes from baseline than those receiving placebo in patient global assessment of disease activity (-20.6 and -20.0 vs -7.4, respectively), patient assessment of pain (-20.8 and -20.4 vs -6.7), psoriatic arthritis quality of life (-3.5 and -3.2 vs -0.4), Dermatology Life Quality Index (-8.8 and -7.9 vs 0.7); p{\textlangle}0.0001 vs placebo for both secukinumab groups for above PROs and Functional Assessment of Chronic Illness Therapy-Fatigue (6.74 (p{\textlangle}0.05 vs placebo) and 6.03 vs 4.00); all of which well exceeded minimum clinically important differences. 
Conclusions: In subjects with PsA, secukinumab treatment resulted in clinically meaningful improvements in global disease activity, pain, generic and disease-specific measures of health-related quality of life and fatigue.},
  author       = {Strand, Vibeke and Mease, Philip and Gossec, Laure and Elkayam, Ori and Van den Bosch, Filip and Zuazo, James and Pricop, Luminita and Mpofu, Shephard},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  keyword      = {QUALITY-OF-LIFE,RHEUMATOID-ARTHRITIS,ANKYLOSING-SPONDYLITIS,PERSPECTIVE,CRITERIA,FATIGUE},
  language     = {eng},
  number       = {1},
  pages        = {203--207},
  title        = {Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1)},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2015-209055},
  volume       = {76},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: